BeiGene
BGNE
#851
Rank
ยฃ18.76 B
Marketcap
ยฃ164.02
Share price
0.87%
Change (1 day)
14.98%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -ยฃ13.93

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -ยฃ13.15. In 2022 the company made an earnings per share (EPS) of -ยฃ15.31 a decrease over its 2021 EPS that were of -ยฃ12.02.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-ยฃ13.93-8.99%
2022-ยฃ15.3127.35%
2021-ยฃ12.02-19.96%
2020-ยฃ15.0220.81%
2019-ยฃ12.4331.52%
2018-ยฃ9.45417.57%
2017-ยฃ1.83-37.16%
2016-ยฃ2.91158.95%
2015-ยฃ1.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-ยฃ0.79-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.21-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA